Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Toon andere (1) versies

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2001

Gelijkaardige items

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
door: Croucher, P, et al.
Gepubliceerd in: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
door: Croucher, P, et al.
Gepubliceerd in: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
door: Croucher, P, et al.
Gepubliceerd in: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
door: Croucher, P, et al.
Gepubliceerd in: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
door: Croucher, P, et al.
Gepubliceerd in: (2002)

Osteoprotegerin and the development of myeloma bone disease
door: Croucher, P, et al.
Gepubliceerd in: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
door: Shipman, C, et al.
Gepubliceerd in: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
door: Vanderkerken, K, et al.
Gepubliceerd in: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
door: Shipman, C, et al.
Gepubliceerd in: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
door: Shipman, C, et al.
Gepubliceerd in: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
door: De Leenheer, E, et al.
Gepubliceerd in: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
door: Shipman, C, et al.
Gepubliceerd in: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
door: Croucher, P, et al.
Gepubliceerd in: (2003)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
door: Croucher, P, et al.
Gepubliceerd in: (2002)

Role of osteoprotegerin (OPG) in cancer.
door: Holen, I, et al.
Gepubliceerd in: (2006)

Bisphosphonates--mechanisms of action in multiple myeloma.
door: Shipman, C, et al.
Gepubliceerd in: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
door: Shipman, C, et al.
Gepubliceerd in: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
door: Shipman, C, et al.
Gepubliceerd in: (2000)

The role of osteoprotegerin in breast and prostate cancer
door: Holen, I, et al.
Gepubliceerd in: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
door: De Leenheer, E, et al.
Gepubliceerd in: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
door: Shipman, C, et al.
Gepubliceerd in: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
door: Shipman, C, et al.
Gepubliceerd in: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
door: Holen, I, et al.
Gepubliceerd in: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
door: Eaton, C, et al.
Gepubliceerd in: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
door: Anđelković Zlatibor, et al.
Gepubliceerd in: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
door: Huan Liu, et al.
Gepubliceerd in: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
door: Mueller, G, et al.
Gepubliceerd in: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
door: Mueller, G, et al.
Gepubliceerd in: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
door: Edwards, C, et al.
Gepubliceerd in: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
door: Holen, I, et al.
Gepubliceerd in: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
door: Eaton, C, et al.
Gepubliceerd in: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
door: Akshitha Devaraj, MBBS, et al.
Gepubliceerd in: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
door: Aiken Dao, et al.
Gepubliceerd in: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
door: Dongyeop Shin, et al.
Gepubliceerd in: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
door: Locklin, R, et al.
Gepubliceerd in: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
door: Waterman, E, et al.
Gepubliceerd in: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
door: Dongzheng Gai, et al.
Gepubliceerd in: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
door: Domingos Sousa, et al.
Gepubliceerd in: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
door: Dirk Hose, et al.
Gepubliceerd in: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
door: Lwin, S, et al.
Gepubliceerd in: (2017)